CLINICAL TRIALS PROFILE FOR FRUQUINTINIB
✉ Email this page to a colleague
505(b)(2) Clinical Trials for Fruquintinib
| Trial Type | Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|---|
| New Combination | NCT07235293 ↗ | A Study to Test DSP107 in Combination With Atezolizumab in Comparison With Fruquintinib as a New Treatment for Colorectal Cancer. | NOT_YET_RECRUITING | Novotech (Australia) Pty Limited | PHASE2 | 2025-11-15 | This clinical study is testing whether a new combination of medicines (DSP107 and atezolizumab) is more effective and safer than an existing treatment (fruquintinib) for people with advanced colorectal cancer that is microsatellite stable (MSS). Participants will be randomly assigned to receive one of the two treatments, and researchers will monitor how well the cancer responds, how safe the treatments are, and how the body processes them. The study hopes to show that the new combination can improve outcomes for patients with this type of colorectal cancer. |
| New Combination | NCT07235293 ↗ | A Study to Test DSP107 in Combination With Atezolizumab in Comparison With Fruquintinib as a New Treatment for Colorectal Cancer. | NOT_YET_RECRUITING | Kahr Bio Australia Pty Ltd | PHASE2 | 2025-11-15 | This clinical study is testing whether a new combination of medicines (DSP107 and atezolizumab) is more effective and safer than an existing treatment (fruquintinib) for people with advanced colorectal cancer that is microsatellite stable (MSS). Participants will be randomly assigned to receive one of the two treatments, and researchers will monitor how well the cancer responds, how safe the treatments are, and how the body processes them. The study hopes to show that the new combination can improve outcomes for patients with this type of colorectal cancer. |
| >Trial Type | >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
All Clinical Trials for Fruquintinib
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT01645215 ↗ | Phase I Study of Fruquintinib(HMPL-013) in Patients With Advanced Solid Tumors | Completed | Fudan University | Phase 1 | 2011-01-01 | Fruquintinib (HMPL-013) is a novel oral small molecule that selectively inhibits vascular endothelial growth factor receptors (VEGFR) 1, 2, and 3 and has demonstrated potent inhibitory effects on multiple human tumor xenografts. This first-in-human study is conducted to assess the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT), to evaluate the pharmacokinetics , safety and preliminary anti-tumor activity of HMPL-013 at single doses and multiple doses . |
| NCT01645215 ↗ | Phase I Study of Fruquintinib(HMPL-013) in Patients With Advanced Solid Tumors | Completed | Hutchison Medipharma Limited | Phase 1 | 2011-01-01 | Fruquintinib (HMPL-013) is a novel oral small molecule that selectively inhibits vascular endothelial growth factor receptors (VEGFR) 1, 2, and 3 and has demonstrated potent inhibitory effects on multiple human tumor xenografts. This first-in-human study is conducted to assess the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT), to evaluate the pharmacokinetics , safety and preliminary anti-tumor activity of HMPL-013 at single doses and multiple doses . |
| NCT01955304 ↗ | Food Effect Study of Single Dose of Fruquintinib (HMPL-013) in Healthy Subjects | Completed | Hutchison Medipharma Limited | Phase 1 | 2012-06-01 | This study will determine the effect of food on the pharmacokinetics (PK) of a single dose of 4mg fruquintinib in normal healthy subjects. |
| NCT01975077 ↗ | A Phase Ib Study of Fruquintinib in 3rd Line mCRC | Completed | Fudan University | Phase 1/Phase 2 | 2012-12-01 | Fruquintinib is a novel oral small molecule compound discovered and developed by Hutchison MediPharma that selectively inhibits vascular endothelial growth factor receptors (VEGFR) 1, 2, and 3 and has demonstrated potent inhibitory effects on multiple human tumor xenografts.Based on first-in-human study, both 4mg QD and 5mg 3wks on/1wk off are safety and efficacy, this phase Ib study is to evaluable the safety, tolerability and efficacy of these 2 regimens with mCRC failed 2nd therapy or more and to determine the recommended dose and regimen in phase II/III study. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Fruquintinib
Condition Name
Clinical Trial Locations for Fruquintinib
Trials by Country
Clinical Trial Progress for Fruquintinib
Clinical Trial Phase
Clinical Trial Sponsors for Fruquintinib
Sponsor Name
